ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0421

Bioinformatics Platform to Study the Genetics of Biologic DMARD Non-responders: Design and Protocol of the RA Non-responders to Treatment (RANT) Study
Abstract Number: 0457

Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival
Abstract Number: 1066

Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
Abstract Number: 2149

Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors
Abstract Number: 0391

Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis
Abstract Number: 0498

Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
Abstract Number: 1302

Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study
Abstract Number: 1780

Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
Abstract Number: 2443

Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus
Abstract Number: 1693

Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
Abstract Number: 1147

Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function
Abstract Number: 1829

Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome
Abstract Number: 1465

Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis
Abstract Number: 1930

Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series
Abstract Number: 0570

BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].